Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Type, By Technology, By Offering, By Application, By End User, By Region and Competition, 2020-2030F
세계의 종양학 및 면역학 유세포 분석 시장은 2024년에 34억 1,000만 달러로 평가되었고, 2030년에는 54억 7,000만 달러에 이를 것으로 예상되며, 예측 기간 동안 CAGR은 8.19%를 나타낼 전망입니다.
시장 성장은 고도의 유세포 분석기의 진화와 함께 암이나 면역학 연구에 있어서 유세포 분석의 유용성이 높아지고 있는 것이 뒷받침되고 있습니다. 면역 마커, 종양 항원의 평가에 필수적입니다. 보급을 뒷받침하고 있습니다. 연구 투자 증가와 질병의 조기 발견의 세계의 중시와 함께, 이러한 요인은 종합적으로 종양학 및 면역학 두 분야에서 유세포 분석의 범위와 응용을 확대하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030 |
| 시장 규모 : 2024년 |
34억 1,000만 달러 |
| 시장 규모 : 2030년 |
54억 7,000만 달러 |
| CAGR : 2025-2030년 |
8.19% |
| 급성장 부문 |
소프트웨어 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
암 이환율 상승으로 진단 수요 견인
주요 시장 과제
높은 비용과 운영의 복잡성
주요 시장 동향
인공지능 및 머신러닝과의 통합
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 유형별(면역학, 종양학)
- 기술별(세포 기반 유세포 분석, 비드 기반 유세포 분석)
- 제공 내용별(시약, 기기, 소모품, 소프트웨어)
- 용도별(중개 연구, 임상 연구)
- 최종 사용자별(병원, 진단 실험실, 참조 실험실, 제약 및 바이오테크놀러지 기업, 학술 및 연구 기관, 계약 조사 기관 등)
- 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
- 기업별(2024년)
- 시장 맵
- 유형별
- 기술별
- 제공별
- 용도별
- 최종 사용자별
- 지역별
제6장 북미의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 종양학 및 면역학 유세포 분석 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 아랍에미리트(UAE)
- 사우디아라비아
- 남아프리카
제11장 시장 역학
제12장 시장 동향과 발전
제13장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 협상력
- 고객의 협상력
- 대체품의 위협/서비스
제14장 세계의 종양학 및 면역학 유세포 분석 시장 : SWOT 분석
제15장 경쟁 구도
- Danaher Corporation
- Merck KGaA
- Miltenyi Biotec
- Neo-Genomics Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Cell Signaling Technology, Inc.
- Becton, Dickinson and Company
- Agilent Technologies, Inc.
- DiaSorin SpA
- OPKO Health, Inc.
제16장 전략적 제안
제17장 기업 소개와 면책사항
KTH
The Global Flow Cytometry in Oncology and Immunology Market was valued at USD 3.41 billion in 2024 and is projected to reach USD 5.47 billion by 2030, growing at a CAGR of 8.19% during the forecast period. Market growth is propelled by the increasing utility of flow cytometry in cancer and immunology research, alongside the evolution of advanced flow cytometers. With cancer ranking among the leading causes of death globally, and immuno-oncology gaining ground as a crucial discipline, there is rising demand for high-precision diagnostic and monitoring tools. Flow cytometry has become indispensable in evaluating cell characteristics, immune markers, and tumor antigens across various sample types. The integration of next-generation flow cytometry tools with therapeutic monitoring and diagnostics, especially in clinical trials for immunotherapies and personalized treatments, is boosting global adoption. Combined with rising research investments and the global emphasis on early disease detection, these factors are collectively expanding the reach and application of flow cytometry in both oncology and immunology.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.41 Billion |
| Market Size 2030 | USD 5.47 Billion |
| CAGR 2025-2030 | 8.19% |
| Fastest Growing Segment | Software |
| Largest Market | North America |
Key Market Drivers
Rising Cancer Incidence Driving Diagnostic Demand
The growing global cancer burden is a key driver for the adoption of flow cytometry in oncology diagnostics. This technique is critical for diagnosing and monitoring blood cancers like leukemia and lymphoma, enabling precise cellular analysis and biomarker identification. As per WHO, cancer accounted for nearly 10 million deaths in 2020, and GLOBOCAN estimates that new cancer cases will surge past 28 million by 2040. Flow cytometry is also instrumental in detecting minimal residual disease (MRD) and supporting treatment decisions. With increasing adoption of immunotherapies and personalized oncology treatments, flow cytometry's role in immune profiling and response monitoring is expanding. In support, organizations like the U.S. National Cancer Institute have committed billions to precision medicine and diagnostics infrastructure, fostering widespread implementation. These efforts underscore flow cytometry's importance in the future of cancer diagnosis and treatment.
Key Market Challenges
High Cost and Operational Complexity
Despite its clinical and research value, flow cytometry adoption is hindered by high operational and capital expenses. The cost of acquiring high-end instruments, software, and consumables is substantial, making it challenging for institutions in developing regions to invest. Additionally, flow cytometry requires technical expertise for calibration, analysis, and interpretation-skills that are often limited in resource-constrained settings. Complex data interpretation can introduce variability and errors, further complicating implementation. The lack of infrastructure and diagnostic capacity in many low- and middle-income countries reinforces disparities in access to this technology. According to WHO data, these regions have significantly fewer diagnostic labs per capita, highlighting access challenges. Addressing these cost and skill barriers is essential to ensuring broader and more equitable utilization of flow cytometry worldwide.
Key Market Trends
Integration with Artificial Intelligence and Machine Learning
A transformative trend in the flow cytometry space is the integration of artificial intelligence (AI) and machine learning (ML) into data processing workflows. Traditional manual gating and analysis can be time-consuming and prone to human error. AI and ML technologies now streamline these processes by automating gating, improving pattern recognition, and extracting high-dimensional insights from complex datasets. In oncology, ML algorithms are being applied to predict treatment outcomes using immune signatures from flow cytometry data. In immunology, these tools aid in identifying rare cell subsets and monitoring immune dynamics with high precision. Global research initiatives like NIH's Bridge2AI and the EU's Horizon Europe are actively funding the incorporation of AI into diagnostics, including flow cytometry. This convergence of data science with laboratory medicine is poised to elevate accuracy, reproducibility, and clinical utility, marking a pivotal evolution in how flow cytometry is applied in healthcare.
Key Market Players
- Danaher Corporation
- Merck KGaA
- Miltenyi Biotec
- Neo-Genomics Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Cell Signaling Technology, Inc.
- Becton, Dickinson and Company
- Agilent Technologies, Inc.
- DiaSorin S.p.A
- OPKO Health, Inc.
Report Scope:
In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Flow Cytometry in Oncology and Immunology Market, By Type:
Flow Cytometry in Oncology and Immunology Market, By Technology:
- Cell-based flow cytometry
- Bead-based flow cytometry
Flow Cytometry in Oncology and Immunology Market, By Offering:
- Reagents
- Instruments
- Consumables
- Software
Flow Cytometry in Oncology and Immunology Market, By Application:
- Translational Research
- Clinical Research
Flow Cytometry in Oncology and Immunology Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
Flow Cytometry in Oncology and Immunology Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.
Available Customizations:
Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Flow Cytometry in Oncology and Immunology Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Immunology, Oncology)
- 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
- 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
- 5.2.4. By Application (Translational Research, Clinical Research)
- 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
- 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
- 5.2.7. By Company (2024)
- 5.3. Market Map
- 5.3.1. By Type
- 5.3.2. By Technology
- 5.3.3. By Offering
- 5.3.4. By Application
- 5.3.5. By End User
- 5.3.6. By Region
6. North America Flow Cytometry in Oncology and Immunology Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Technology
- 6.2.3. By Offering
- 6.2.4. By Application
- 6.2.5. By End User
- 6.2.6. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Technology
- 6.3.1.2.3. By Offering
- 6.3.1.2.4. By Application
- 6.3.1.2.5. By End User
- 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Technology
- 6.3.2.2.3. By Offering
- 6.3.2.2.4. By Application
- 6.3.2.2.5. By End User
- 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Technology
- 6.3.3.2.3. By Offering
- 6.3.3.2.4. By Application
- 6.3.3.2.5. By End User
7. Europe Flow Cytometry in Oncology and Immunology Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Technology
- 7.2.3. By Offering
- 7.2.4. By Application
- 7.2.5. By End User
- 7.2.6. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Technology
- 7.3.1.2.3. By Offering
- 7.3.1.2.4. By Application
- 7.3.1.2.5. By End User
- 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Technology
- 7.3.2.2.3. By Offering
- 7.3.2.2.4. By Application
- 7.3.2.2.5. By End User
- 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Technology
- 7.3.3.2.3. By Offering
- 7.3.3.2.4. By Application
- 7.3.3.2.5. By End User
- 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Technology
- 7.3.4.2.3. By Offering
- 7.3.4.2.4. By Application
- 7.3.4.2.5. By End User
- 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Technology
- 7.3.5.2.3. By Offering
- 7.3.5.2.4. By Application
- 7.3.5.2.5. By End User
8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Technology
- 8.2.3. By Offering
- 8.2.4. By Application
- 8.2.5. By End User
- 8.2.6. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Technology
- 8.3.1.2.3. By Offering
- 8.3.1.2.4. By Application
- 8.3.1.2.5. By End User
- 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Offering
- 8.3.2.2.4. By Application
- 8.3.2.2.5. By End User
- 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By Offering
- 8.3.3.2.4. By Application
- 8.3.3.2.5. By End User
- 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Technology
- 8.3.4.2.3. By Offering
- 8.3.4.2.4. By Application
- 8.3.4.2.5. By End User
- 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Technology
- 8.3.5.2.3. By Offering
- 8.3.5.2.4. By Application
- 8.3.5.2.5. By End User
9. South America Flow Cytometry in Oncology and Immunology Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Technology
- 9.2.3. By Offering
- 9.2.4. By Application
- 9.2.5. By End User
- 9.2.6. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Offering
- 9.3.1.2.4. By Application
- 9.3.1.2.5. By End User
- 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Offering
- 9.3.2.2.4. By Application
- 9.3.2.2.5. By End User
- 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Offering
- 9.3.3.2.4. By Application
- 9.3.3.2.5. By End User
10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Technology
- 10.2.3. By Offering
- 10.2.4. By Application
- 10.2.5. By End User
- 10.2.6. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Offering
- 10.3.1.2.4. By Application
- 10.3.1.2.5. By End User
- 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Offering
- 10.3.2.2.4. By Application
- 10.3.2.2.5. By End User
- 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Offering
- 10.3.3.2.4. By Application
- 10.3.3.2.5. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challanges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porters Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products/Services
14. Global Flow Cytometry in Oncology and Immunology Market: SWOT Analysis
15. Competitive Landscape
- 15.1. Danaher Corporation
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. Merck KGaA
- 15.3. Miltenyi Biotec
- 15.4. Neo-Genomics Laboratories, Inc.
- 15.5. Thermo Fisher Scientific Inc.
- 15.6. Cell Signaling Technology, Inc.
- 15.7. Becton, Dickinson and Company
- 15.8. Agilent Technologies, Inc.
- 15.9. DiaSorin S.p.A
- 15.10. OPKO Health, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
